Macrophage Recruitment in Immune-Privileged Lens During Capsule Repair, Necrotic Fiber Removal and Fibrosis

2021 ◽  
Author(s):  
Yuting Li ◽  
Zhen Li ◽  
Yumeng Quan ◽  
Hongyun Cheng ◽  
Manuel Riquelme ◽  
...  
iScience ◽  
2021 ◽  
pp. 102533
Author(s):  
Yuting Li ◽  
Zhen Li ◽  
Yumeng Quan ◽  
Hongyun Cheng ◽  
Manuel A. Riquelme ◽  
...  

Author(s):  
Christian Schuster ◽  
Arnaud Huard ◽  
Evelyn Sirait-Fischer ◽  
Christina Dillmann ◽  
Bernhard Brüne ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Sibel Durlanik ◽  
Katrin Fundel-Clemens ◽  
Coralie Viollet ◽  
Heinrich J. Huber ◽  
Martin Lenter ◽  
...  

AbstractMore than 70% of colorectal, prostate, ovarian, pancreatic and breast cancer specimens show expression of CD276 (B7–H3), a potential immune checkpoint family member. Several studies have shown that high CD276 expression in cancer cells correlates with a poor clinical prognosis. This has been associated with the presence of lower tumor infiltrating leukocytes. Among those, tumor-associated macrophages can comprise up to 50% of the tumor mass and are thought to support tumor growth through various mechanisms. However, a lack of information on CD276 function and interaction partner(s) impedes rigorous evaluation of CD276 as a therapeutic target in oncology. Therefore, we aimed to understand the relevance of CD276 in tumor-macrophage interaction by employing a 3D spheroid coculture system with human cells. Our data show a role for tumor-expressed CD276 on the macrophage recruitment into the tumor spheroid, and also in regulation of the extracellular matrix modulator PAI-1. Furthermore, our experiments focusing on macrophage-expressed CD276 suggest that the antibody-dependent CD276 engagement triggers predominantly inhibitory signaling networks in human macrophages.


Life Sciences ◽  
2021 ◽  
pp. 119839
Author(s):  
Amy A. Powers ◽  
Katherine E. Jones ◽  
Seth H. Eisenberg ◽  
Lora H. Rigatti ◽  
John P. Ryan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document